Why CareDx Stock Jumped Today
CareDx (CDNA) shares rose 14.72% after the company raised its full-year sales and earnings outlook. In Q2, revenue grew 52% to $132 million and adjusted net income rose to $20 million, or $0.37 per share. CareDx increased FY revenue guidance to $490M-$500M and EBITDA to $66M-$78M, citing demand and reimbursement coverage.
How this was made
The 30-second read
Why it matters
Q2 revenue growth (+52% YoY to $132M) and a large adjusted net income improvement ($20M, $0.37/share) led management to lift FY revenue and adjusted EBITDA ranges, driving the stock’s sharp move.
Market read
This is a beat-and-raise story with explicit FY guidance ranges, making it actionable for traders managing near-term expectations and valuation.
What to watch
The article cites CMS coverage affirmation and Naveris acquisition, but does not quantify integration benefits or margin sustainability, which could drive volatility after the initial pop.
Background
CareDx provides non-invasive molecular diagnostics for transplant patient monitoring, with CMS coverage for surveillance testing affirmed earlier in the month.
Ticker impact
CareDx raised full-year revenue guidance to $490M-$500M and adjusted EBITDA to $66M-$78M after Q2 results beat estimates.
Near-term upside bias as traders reprice the raised FY revenue and EBITDA range; follow-through depends on whether transplant testing demand and reimbursement remain durable.
The article attributes the +14.72% move directly to lifted full-year sales and earnings forecasts, with specific numeric ranges and a beat on adjusted net income per share.
Market effects
Supports sentiment for precision diagnostics and transplant surveillance testing reimbursement durability.
Primarily US healthcare diagnostics sentiment; limited direct regional spillover described.
No explicit global catalyst beyond US reimbursement coverage and company guidance.
Counterpoint
Guidance raises may already be partially anticipated; upside could fade if the raised ranges rely on continued reimbursement and testing activity that can fluctuate.
Key entities
- companyCareDx
Precision molecular diagnostics provider; raised full-year revenue and adjusted EBITDA guidance after Q2 beat.
- companyNaveris
Oncology diagnostics provider acquired by CareDx to accelerate expansion.
- regulatorCenters for Medicare & Medicaid Services (CMS)
Affirmed coverage for CareDx surveillance testing for kidney, heart, and lung transplants earlier in the month.
